Axis Securities: Risk Calibration For 2021
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Axis Securities Report
Moderation of Covid-19 cases continued in November with a drop of 30% month-on-month. Covid-19 situation appears to be improving since last two months with the average daily cases reducing to 45,000 per day in November versus 60, 000 in previous month.
44 vaccination candidates are in various stages of development of the Corona vaccine, out of which 10 candidates are now in Phase three trial which is a final phase of the vaccine development.
Earlier this month, two vaccine candidates from Pfizer Ltd. and Moderna have shown upbeat results with an efficacy rate of almost 95%.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.